Associations between dermatologic immune-related adverse event morphologies and systemic immunomodulatory/immunosuppressive treatment: A large retrospective cohort study

To the Editor: Among patients with cancer receiving immune checkpoint inhibitor (ICI) therapy, dermatologic immune-related adverse events (D-irAEs) are the earliest arising and most common irAEs. It remains challenging to optimize D-irAE management while pursuing overall oncology treatment goals.1,2 In this single-institution retrospective cohort study, we evaluate the relationships between distinct D-irAE morphologies and treatments utilized in their care.

https://www.jaad.org/article/S0190-9622(24)00309-8/fulltext?rss=yes

Source: Journal of the American Academy of Dermatology - February 8, 2024 Category: Dermatology Authors: Rachel M. Reardon, Katherine L. Perlman, Maria S. Asdourian, Nishi Shah, Ted V. Jacoby, Leah L. Thompson, Kerry L. Reynolds, Yevgeniy R. Semenov, Steven T. Chen Tags: Research letter Source Type: research